Eosinophilic oesophagitis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IL-15 0
• IL-4 0
• TSLP 0

24 of 250 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDDK · R01

  A Pilot Feasibility Study of Esophageal Antigen Test (EAT) Directed Diet versus Sham Diet for treatment of Eosinophilic Esophagitis: Novel Insights

  Utah State Higher Education System--University of Utah· Salt Lake City, United States· US$308,000 awarded in fiscal year 2026· until May 2029

• NIH NIDDK · R01

  A pilot feasibility study of novel, non-invasive EoE food tests

  Children's Hosp of Philadelphia· Philadelphia, United States· US$356,000 awarded in fiscal year 2026· until Jun 2029

• NIH NIAID · R01

  Gastrointestinal tissue-adapted eosinophils in health and disease

  University of Colorado Denver· Aurora, United States· US$771,983 awarded in fiscal year 2026· until Aug 2031

• NIH NIAID · R01

  Allergic eosinophilic esophagitis drives dysregulated innate immunity in esophageal fibroblasts

  University of California, San Diego· La Jolla, United States· US$1,496,677 awarded in fiscal year 2026· until Jun 2031

• NIH NIDDK · R01

  Towards Multi-modal Biomarker and Personalized Medicine: Integrating Esophageal Biochemical, Structural, and Molecular Alterations in Pediatric Eosinophilic Esophagitis

  Vanderbilt University Medical Center· Nashville, United States· US$668,544 awarded in fiscal year 2026· until Feb 2031

5 of 50 running projects, newest first. Listed amounts together: US$33.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Morphological Markers of Gastroesophageal Reflux Disease (GERD)

  NCT01921686· Baylor College of Medicine· Updated 17 Aug 2026

  “Study objectives were not met and lack of funding”Registry text, quoted unchanged. Source

• Withdrawn

  Imaging of the Esophagus Using a SECM Capsule

  NCT03546660· Massachusetts General Hospital· Updated 22 Oct 2025

  “We are currently working and developing our technology to ensure accurate data collection and safety. We will re-open in the future for recruitment.”Registry text, quoted unchanged. Source

• Withdrawn

  Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)

  NCT05214599· Bazell Pharma AG· Updated 23 Aug 2024

  “Business decision”Registry text, quoted unchanged. Source

• Terminated

  Systems Biology of Gastrointestinal and Related Diseases

  NCT05579444· Viome· Updated 15 Dec 2023

  “Lack of enrollment.”Registry text, quoted unchanged. Source

• Withdrawn

  Non-endoscopic Tracking of Disease Activity in Eosinophilic Esophagitis

  NCT03834298· University of Colorado, Denver· Updated 31 Mar 2023

  “Study grant not obtained; not moving forward with study at this time.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Natural History and Genetics of Food Allergy and Related Conditions

  NCT02504853· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis

  2026-526348-11-01· Amsterdam UMC Stichting· Source

• Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

  NCT05583227· AstraZeneca· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

  NCT07588568· University of North Carolina, Chapel Hill· Source

• A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

  NCT06101095· Sanofi· Source

• A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

  NCT07112378· Regeneron Pharmaceuticals· Source

• A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

  NCT06695897· Sanofi· Source

• Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

  NCT06596252· Dr. Falk Pharma GmbH· Source

• The DiNAM-EoE-C Study: Esophageal Distensibility and Novel Assessment of Motility in Eosinophilic Esophagitis

  NCT07708467· Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Organoids 1
• Mendelian Randomization Analysis 1
• Gene Expression Profiling 7
• Proteomics 1
• Immunohistochemistry 1
• Machine Learning 1
• Cohort Studies 10
• Genome-Wide Association Study 2

See which targets of this disease your abstract mentions, and go to the people working on them.